Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of nintedanib for systemic sclerosis-associated interstitial lung disease
MOH_2018-05-16_002383Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of nintedanib, sponsored by Boehringer Ingelheim. Started Mar 2018; status: active, not recruiting.
02
Drugs
nintedanib
Beyond the preview
Go deeper on MOH_2018-05-16_002383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-16_002383.